Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relay Therapeutics

2.78
+0.09003.35%
Volume:1.51M
Turnover:4.11M
Market Cap:471.27M
PE:-1.18
High:2.79
Open:2.57
Low:2.53
Close:2.69
Loading ...

Relay Therapeutics, Inc. : Wells Fargo Initiates Coverage With Equal Weight Rating and Target Price $4

THOMSON REUTERS
·
17 Apr

Relay Therapeutics initiated with an Equal Weight at Wells Fargo

TIPRANKS
·
17 Apr

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Insider Monkey
·
16 Apr

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

Zacks
·
16 Apr

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!

Insider Monkey
·
31 Mar

Relay Therapeutics weakness brings buying opportunity, says Barclays

TIPRANKS
·
30 Mar

Relay Therapeutics weakness brings buying opportunity, says Barclays

TIPRANKS
·
27 Mar

Relay Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Relay Therapeutics: Promising Clinical Trials and Strategic Positioning Justify Buy Rating

TIPRANKS
·
07 Mar

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)

Zacks
·
05 Mar

Bank of America Securities Sticks to Their Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
28 Feb

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Reuters
·
28 Feb

Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial Developments

TIPRANKS
·
28 Feb

Relay Therapeutics Is Maintained at Buy by Goldman Sachs

Dow Jones
·
28 Feb

Stock Track | Relay Therapeutics Plummets 13.33% as Missed Revenue Expectations and Losses Weigh on Shares

Stock Track
·
27 Feb

Relay Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

TD Cowen Sticks to Their Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
27 Feb

Relay Therapeutics reports Q4 EPS (45c), consensus (55c)

TIPRANKS
·
27 Feb

Relay Therapeutics Q4 GAAP EPS $(0.45) Beats $(0.58) Estimate

Benzinga
·
27 Feb

BRIEF-Relay Therapeutics Q4 Net Income USD -76.004 Million

Reuters
·
27 Feb